BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 30053724)

  • 21. Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies.
    Debattista J; Grech L; Scerri C; Grech G
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Yörüker EE; Holdenrieder S; Gezer U
    Clin Chim Acta; 2016 Apr; 455():26-32. PubMed ID: 26797671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis.
    Tóth K; Barták BK; Tulassay Z; Molnár B
    Expert Rev Mol Diagn; 2016; 16(2):239-52. PubMed ID: 26652067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-Free DNA in the Management of Colorectal Cancer.
    Harlé A
    Recent Results Cancer Res; 2020; 215():253-261. PubMed ID: 31605233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
    Spindler KG
    Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplexed DNA Methylation Analysis in Colorectal Cancer Using Liquid Biopsy and Its Diagnostic and Predictive Value.
    Pulverer W; Kruusmaa K; Schönthaler S; Huber J; Bitenc M; Bachleitner-Hofmann T; Bhangu JS; Oehler R; Egger G; Weinhäusel A
    Curr Issues Mol Biol; 2021 Oct; 43(3):1419-1435. PubMed ID: 34698107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid biopsy in CNS tumors: Current status & future perspectives.
    Husain N; Husain A; Mishra S; Srivastava P
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future perspectives of circulating tumor DNA in colorectal cancer.
    Nadal C; Winder T; Gerger A; Tougeron D
    Tumour Biol; 2017 May; 39(5):1010428317705749. PubMed ID: 28488528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methods for Measuring ctDNA in Lymphomas.
    Rossi D; Condoluci A; Spina V; Gaidano G
    Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?
    Kahlert C
    Cancer Res; 2019 May; 79(10):2462-2465. PubMed ID: 31043377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection.
    Barták BK; Kalmár A; Galamb O; Wichmann B; Nagy ZB; Tulassay Z; Dank M; Igaz P; Molnár B
    Pathol Oncol Res; 2019 Jul; 25(3):915-923. PubMed ID: 29374860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating cell-free nucleic acids: characteristics and applications.
    Pös O; Biró O; Szemes T; Nagy B
    Eur J Hum Genet; 2018 Jul; 26(7):937-945. PubMed ID: 29681621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid Biopsy in Solid Malignancy.
    Scarlotta M; Simsek C; Kim AK
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):284-296. PubMed ID: 30916594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
    Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer.
    Wang JJ; Wang X; Song YX; Zhao JH; Sun JX; Shi JX; Wu ZH; Wang ZN
    Dis Markers; 2019; 2019():2587109. PubMed ID: 31275444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
    Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
    PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.
    Siravegna G; Bardelli A
    Mol Oncol; 2016 Mar; 10(3):475-80. PubMed ID: 26774880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer.
    Boysen AK; Sørensen BS; Lefevre AC; Abrantes R; Johansen JS; Jensen BV; Schou JV; Larsen FO; Nielsen D; Taflin H; Gustavson B; Wettergren Y; Sorensen BS; Ree AH; Dueland S; Pallisgaard N; Spindler KL
    Clin Chim Acta; 2018 Dec; 487():107-111. PubMed ID: 30240586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Circulating Tumor DNA in Colorectal Cancer.
    Li H; Lu S; Zhou Z; Zhu X; Shao Y
    Methods Mol Biol; 2023; 2695():227-236. PubMed ID: 37450122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.